India's Cipla says supply of Covid-19 drug remdesivir catching up with demand - Hindustan Times
close_game
close_game

India's Cipla says supply of Covid-19 drug remdesivir catching up with demand

Reuters |
May 15, 2021 08:22 PM IST

Cipla, one of India's oldest drug manufacturers, has a deal to make and supply remdesivir to more than 100 countries.

India's Cipla said on Saturday that its manufacturing of the Covid-19 remdesivir drug was beginning to catch up with demand after the company sought to boost production amid a massive second wave of coronavirus infections in the country.

On Friday, Cipla reported a 68.1% jump in fourth-quarter consolidated net profit and a 6.6% rise in sales.(Reuters)
On Friday, Cipla reported a 68.1% jump in fourth-quarter consolidated net profit and a 6.6% rise in sales.(Reuters)

Backorders and complaints over low supply started moderating in the second week of May, the drugmaker said, after it began ramping up production of the antiviral drug last month.

Hindustan Times - your fastest source for breaking news! Read now.

Hospitals have faced shortages of the drug, which is being widely used and was sold in April for over 10 times its listed price in the black market.

Cipla's production of remdesivir is currently 5 times higher than the monthly output of 200,000 to 300,000 vials seen in the last wave of the pandemic last year, the company's Chief Financial Officer Kedar Upadhye told Reuters. Remdesivir was originally developed by U.S.-based Gilead Sciences Inc.

Future supply of the drug will also depend on the course of the pandemic in India but "manufacturing is no longer the bottleneck," Upadhye said.

The number of complaints about supply has dropped, Upadhye said, adding that Cipla was working with state governments to tackle ongoing supply shortages in parts of the country.

Cipla, one of India's oldest drug manufacturers, has a deal to make and supply remdesivir to more than 100 countries. Several other Indian drug producers have similar agreements.

The company has also signed licensing agreements with U.S. companies Merck and Eli Lilly to make and sell Merck's experimental Covid-19 drug molnupiravir and Lilly's arthritis drug baricitinib, which is also being used to treat Covid-19, in India.

On Friday, Cipla reported a 68.1% jump in fourth-quarter consolidated net profit and a 6.6% rise in sales.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away!- Login Now!
Stay informed on Business News along with Gold Rates Today, India News and other related updates on Hindustan Times Website and APPs
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On